Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients

Published:2019-06-14 Issue:2 Volume:84 Page:275-280
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Hosoya Kazutaka,Fujimoto Daichi^ORCID,Kawachi Hayato,Sato Yuki,Kogo Mariko,Nagata Kazuma,Nakagawa Atsushi,Tachikawa Ryo,Hiraoka Shinya,Kokubo Masaki,Tomii Keisuke

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03885-4.pdf

Reference22 articles.

1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387

2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241. https://doi.org/10.3322/caac.21149

3. Morgensztern D, Ng S, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:29–33

4. Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8:1–20. https://doi.org/10.5306/wjco.v8.i1.1

5. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study;Clinical Lung Cancer;2024-07

2. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer;Radiation Oncology;2023-05-22

3. Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study;Thoracic Cancer;2023-01-10

4. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer;2022-08-22

5. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors;Immunotherapy;2022-08